PAION ANNOUNCES THAT NMPA ACCEPTS SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BESYLATE IN GENERAL ANESTHESIA BY CHINESE LICENSEE YICHANG HUMANWELL
DGAP-News: PAION AG / Key word(s): Regulatory Admission PAION ANNOUNCES THAT NMPA ACCEPTS SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BESYLATE IN GENERAL ANESTHESIA BY CHINESE LICENSEE YICHANG HUMANWELL
Yichang Humanwell recently successfully completed the clinical development for remimazolam besylate in general anesthesia. Dr. Jim Phillips, CEO of PAION AG, commented: "Yichang Humanwell has already made great progress in the China market with Ruima(R) (remimazolam besylate) in procedural sedation, exceeding our initial expectations. We are therefore very pleased that the second indication for use in general anesthesia has been submitted under an NDA, and look forward to the outcome of the NMPA review, and possibly further market expansion for use." Byfavo(R) (remimazolam besylate) About PAION In addition to Byfavo(R), PAION is preparing to launch the two products GIAPREZA(R) (angiotensin II) and XERAVA(R) (eravacycline) in Europe. Giapreza is a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. Xerava is a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. PAION's mission is to be a leading specialty pharmaceutical company in the fields of anesthesia and critical care by bringing novel products to market to benefit patients, doctors and other stakeholders in healthcare. PAION is headquartered in Aachen (Germany). Contact Disclaimer: 09.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | PAION AG |
Heussstraße 25 | |
52078 Aachen | |
Germany | |
Phone: | +49 (0)241-4453-0 |
Fax: | +49 (0)241-4453-100 |
E-mail: | info@paion.com |
Internet: | www.paion.com |
ISIN: | DE000A0B65S3 |
WKN: | A0B65S |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1216736 |
End of News | DGAP News Service |